Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD
M. Sadiq (Gothenburg, Sweden), H. Yu (Gaithersburg, United States), M. Astrand (Gothenburg, Sweden), I. Scott (Cambridge, United Kingdom), A. Williams (Cambridge, United Kingdom), L. Hewitt (Gaithersburg, United States), N. White (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), M. Gavala (Gaithersburg, United States), F. Reid (Cambridge, United Kingdom), C. Kell (Cambridge, United Kingdom), H. Pandya (Cambridge, United Kingdom), E. Jimenez (Barcelona, Spain)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Sadiq (Gothenburg, Sweden), H. Yu (Gaithersburg, United States), M. Astrand (Gothenburg, Sweden), I. Scott (Cambridge, United Kingdom), A. Williams (Cambridge, United Kingdom), L. Hewitt (Gaithersburg, United States), N. White (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), M. Gavala (Gaithersburg, United States), F. Reid (Cambridge, United Kingdom), C. Kell (Cambridge, United Kingdom), H. Pandya (Cambridge, United Kingdom), E. Jimenez (Barcelona, Spain). Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD. 3201
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|